Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Scrip: industry news and insights

From licensing to clinical trials to competitor activity, stay current on business developments in your market.

Understand what’s happening in the market right now and what it means for the future of your business with news and insight from our team of journalists and analysts. Scrip is essential for anyone making commercial decisions in the pharmaceutical industry.

Start a free trial

Follow market developments
Go beyond the news
Hear from news makers

Go behind the headlines

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Start a free trial

What's included

Follow market developments

Scrips global team of journalists span key markets around the clock

Go beyond the news

Get exclusive access to accurate data, timely insights and trusted analysis that delivers to gain competitive advantage

Hear from news makers

Access interviews with leading decision makers, industry experts and thought leaders, across the industry.

Ask the expert

Put your questions about any of our news stories, data and analysis to our expert journalists and analysts.

Scrip

A timeline of the Takeda/Shire merger

By Mike Ward 15 Apr 2019

A staple of consumer magazines and tabloid newspapers involves coverage of celebrity relationships – who has been seen together? Who is dating? Will they become a permanent item? And are they going to live happily ever after? Readers can’t seem to get enough of it. Interestingly, while maybe not so racy as the celebrity goings-on, pharma industry watchers are keen to follow company couplings. Talk of mergers and acquisitions, one of the ways that companies can build scale, always attracts attention.

Topic Business strategies Company analysis

View interactive data
Scrip

PBMs Were On Capitol Hill, But Pharma Still Took Some Heat

By Jessica Merrill 11 Apr 2019

Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.

Topic Drug approval Drug development landscape Drug review

View article
Scrip

Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

By Mandy Jackson 11 Apr 2019

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Topic BioPharmaceutical

View article
Pink Sheet, Scrip

Scrip and Pinksheet: Comprehensive Coverage from Policy to Strategic Impact

09 Apr 2019

Together, Scrip and Pink Sheet are your winning strategic advantage amidst today’s uncertain global political climate and shifting policy focus. By subscribing to Scrip in concert with Pink Sheet, you gain a a clear line of site between regulation and policy changes and their impact on business strategies, technology investments, clinical trial developments, industry partnerships and much more.

Topic Drug approval Drug review Digital Health

Single report
Scrip

India’s Top Court Tells Singhs To Come Up With Plan To Pay Daiichi, Uphold Nation’s ‘Honor’

By Penelope MacRae 22 Mar 2019

India’s Supreme Court has told Malvinder Singh and Shivinder Singh, once corporate billionaires, to work out a strategy within two weeks to pay Japanese drug giant Daiichi Sankyo a $500m arbitration award and "uphold the nation’s honor."

Topic Business strategies Deal trends

View article
Scrip

Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock

By Cathy Kelly 22 Mar 2019

Public statements by Novartis and Avexis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?

Topic Drug review Drug approval

View article
Scrip

Bayer Bosses Beg Risk-Averse Europe To Rethink

By Kevin Grogan 07 Mar 2019

The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

Topic Cell and gene therapy

View article
Scrip

Asia Deal Watch: Bharat Expands Its Vaccine Holdings By Buying GSKs Chiron Behring

By Anju Ghangurde 07 Mar 2019

Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.

Topic Drug approval Business strategies

View article
Scrip

Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore

By Ian Haydock 27 Feb 2019

Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.

Topic Research

View article
Scrip

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

By Jessica Merrill 27 Feb 2019

Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.

Topic Drug review

View article
Scrip

Mortality Signal For Pfizers Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class

By Emily Hayes 21 Feb 2019

Analyst speculates that risk of pulmonary embolism for a higher unapproved of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.

Topic Arthritis

View article
Scrip

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

By Kevin Grogan 21 Feb 2019

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.

View article
Scrip, Pink Sheet

Webinar: What’s the Reality of Real World Evidence?

By Mary Jo Laffler 19 Feb 2019

The data and analysis for this webinar were drawn from Pink Sheet and Scrip, both part of the Informa Pharma Intelligence suite of intelligence solutions.

Full video
Scrip

In NASH, Gilead Swung For The Fences And Struck Out Again

By Joseph Haas 14 Feb 2019

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.

Topic Drug review Drug approval Drug development landscape Clinical trials

View article
Scrip

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

By John Davis 14 Feb 2019

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.

Topic Cancer

View article

Latest headlines

Scrip

24 Apr 2019

Hepalink-Backed HighTide Bets On NASH For Global Markets

Link
Scrip

23 Apr 2019

Novartis’s Zolgensma In Spotlight As Second Death Is Probed

Link
Scrip

23 Apr 2019

Q1 Drug Sales, Pipeline, 2019 Catalysts Top Themes For AstraZeneca Update

Link
Scrip

23 Apr 2019

Bristol’s Focus Returns To IO Following Celgene Vote

Link
Scrip

23 Apr 2019

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

Link
Scrip

23 Apr 2019

Japan's Healios Progresses Novel Cell Therapy For ARDS

Link
Scrip

23 Apr 2019

Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes

Link
Scrip

23 Apr 2019

Pipeline Watch: Phase III Starts For Lumasiran, CS1001 And Sepofarsen

Link
Scrip

22 Apr 2019

Poseida's CAR-T, Gene Therapy Programs Get $142m Boost, Including Novartis Cash

Link
Scrip

19 Apr 2019

Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results

Link
Scrip

19 Apr 2019

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

Link
Scrip

19 Apr 2019

Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund

Link
Scrip

18 Apr 2019

BI Bets On Expanding Jardiance As Diabetes Drug Sales Soar

Link
Scrip

18 Apr 2019

Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies

Link
Scrip

18 Apr 2019

Asia Executives On The Move: New Daiichi CEO, WuXi CMO

Link

Meet the team

Editor

Brenda Sandburg

Editor, Senior Editor

New York

Brenda specializes in

Policy & Regulation
Biosimilars
Biotech
Generics
Pricing & Reimbursement

+38 year(s) experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC

Cathy specializes in

Policy & Regulation
Market Intelligence
Market Access
Pricing & Reimbursement

+38 year(s) experience

Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC

Denise specializes in

Commercial Strategy
Policy & Regulation

+37 year(s) experience

See all analysts

How we've helped other businesses

"Scrip helps me to stay current with pharmaceutical news on a world-wide basis."

Wendy Johnson CEO, Aires Pharmaceuticals, USA

"RxScorecard™ provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology."

Chronis H. Manolis, RPh Vice President, Pharmacy UPMC Health Plan

"RxScorecard™ lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment."

Ammar Qadan Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers Halozyme Therapeutics, Inc.

Next steps

Request a Trial

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Scrip: industry news and insights

​Go behind the headlines

What's included

Below are the Feature List

Follow market developments

Go beyond the news

Hear from news makers

Ask the expert

Pharma Intelligence: latest

Latest headlines

Meet the team

Below are the Analyst Profile

Brenda Sandburg

Editor, Senior Editor

Cathy Kelly

Editor, Senior editor

Denise Peterson

Management, Editor In Chief, Pharma US

How we've helped other businesses

Related Products

Datamonitor Healthcare: data analysis and insight

Medtrack: full healthcare business coverage

Trialtrove: gold standard clinical trials intelligence

Next steps

This is Contactus Section

Request a Trial

How can we help you?

Pharma Report Store

Go behind the headlines